Nomura Holdings, Inc. (TYO:8604)
888.30
+4.50 (0.51%)
May 30, 2025, 3:30 PM JST
Nomura Holdings Revenue
In the fiscal year ending March 31, 2025, Nomura Holdings had annual revenue of 1.89T JPY with 21.16% growth. Nomura Holdings had revenue of 452.74B in the quarter ending March 31, 2025, with 1.71% growth.
Revenue
1,892.49B
Revenue Growth
+21.16%
P/S Ratio
1.41
Revenue / Employee
70.48M
Employees
26,850
Market Cap
2,665.14B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 1,892.49B | 330.49B | 21.16% |
Mar 31, 2024 | 1,562.00B | 226.42B | 16.95% |
Mar 31, 2023 | 1,335.58B | -28.31B | -2.08% |
Mar 31, 2022 | 1,363.89B | -44.98B | -3.19% |
Mar 31, 2021 | 1,408.87B | 123.04B | 9.57% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Mitsubishi UFJ Financial Group | 8,004.64B |
Sumitomo Mitsui Financial Group | 5,219.82B |
Tokio Marine Holdings | 7,980.93B |
Mizuho Financial Group | 3,883.97B |
JAPAN POST BANK | 1,708.45B |
MS&AD Insurance Group Holdings | 6,435.19B |
Japan Post Holdings | 11.47T |
Dai-ichi Life Holdings | 9,300.89B |
Nomura Holdings News
- 1 day ago - Nomura hails progress in weaning staff off smoking - Financial Times
- 2 days ago - Japan's Nomura stays committed to growth in U.S. despite turmoil - Seeking Alpha
- 2 days ago - Japan's Nomura committed to growth of US business, CEO says - Reuters
- 9 days ago - Nomura maintains ‘Neutral’ on Sun Pharma, flags margin risks as investments rise in FY26 - Business Upturn
- 11 days ago - Brokerage radar: Hindalco, BEL, Dixon, Zydus, Gland Pharma in focus after Q4; target prices revised - Business Upturn
- 19 days ago - Nomura upgrades China stocks to ‘tactical overweight’ after tentative trade breakthrough - South China Morning Post
- 19 days ago - Citi, Nomura cautious on pharma after US price control move; Sun Pharma seen at risk - Business Upturn
- 26 days ago - Nomura pinches JPMorgan managing director - The Australian Financial Review